Zimmer Biomet Holdings Inc. (NYSE: ZBH) is showing strong market presence with its Q4 earnings, robust demand for knee and hip devices outpacing estimates, and financial results for Q1 2024 seeing an expansion in margins. An investment of $3.47M was made by Commerce Bank, amidst others like SageView Advisory Group LLC and Assetmark Inc. acquiring more shares in ZBH. The company beat its EPS forecast by 14%. Despite some periodic underperformance compared to competitors, return trends look promising and it maintains a 'Buy' rating from BTIG, with value stock credentials also being recognized. In governance, Zimmer Biomet has enhanced its employee investment plan. With its upcoming 2024 Investor Day, ZBH aims to outline strategies to deliver above-market growth. The company also witnessed proliferation in its net sales with a 5% increase in Q3 2023. However, concerning the dividends, they will stand at $0.24. Moreover, Zimmer Biomet aims for steady medical devices demand to drive its upbeat profit forecast for 2024. It continues to innovate, with its ROSA Shoulder System granted FDA clearance, showcasing its comprehensive portfolio at AAOS 2024 Annual Meeting. Lastly, appointment of Louis A. Shapiro to their Board of Directors marks an important update in their executive leadership.
Zimmer Biomet Holdings ZBH News Analytics from Tue, 05 Sep 2023 07:00:00 GMT to Thu, 30 May 2024 16:21:00 GMT -
Rating 4
- Innovation 3
- Information 7
- Rumor -1
